iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS - Free Report) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.

Other analysts also recently issued research reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Friday, January 10th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating on the stock in a research report on Thursday, December 19th.

iTeos Therapeutics Trading Down 0.5 %

Shares of NASDAQ ITOS traded down $0.04 during midday trading on Thursday, reaching $7.74. The company's stock had a trading volume of 174,893 shares, compared to its average volume of 316,439. The stock has a 50 day simple moving average of $8.05 and a 200-day simple moving average of $11.61. The stock has a market capitalization of $282.56 million, a price-to-earnings ratio of -2.46 and a beta of 1.39. iTeos Therapeutics has a fifty-two week low of $7.09 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.18) by $0.13. As a group, equities analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current year.

Insider Activity

In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 12.50% of the stock is owned by insiders.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ITOS. State Street Corp boosted its holdings in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after buying an additional 211,452 shares during the period. Dimensional Fund Advisors LP lifted its position in iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock worth $13,481,000 after acquiring an additional 117,159 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock worth $6,540,000 after acquiring an additional 20,092 shares during the period. JPMorgan Chase & Co. grew its position in shares of iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock valued at $4,771,000 after purchasing an additional 5,368 shares during the last quarter. Finally, Algert Global LLC increased its stake in shares of iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock worth $2,615,000 after purchasing an additional 122,730 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.